Drug intelligence / Profile preview

CRO-71

Development stage: Preclinical
Lead developer: Noxopharm
Modality: Small Molecules

Overview

CRO-71 is an experimental drug developed as part of Noxopharm's Chroma technology platform. It has demonstrated significant anti-tumor activity in preclinical models, specifically showing a reduction in the growth of glioblastoma explants by an average of 75.94%. The precise mechanism of action, molecular target, and chemical structure have not been publicly disclosed. Its primary indication appears to be for the treatment of glioblastoma or other brain tumors[1].

Beyond the preview

Go deeper on CRO-71.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRO-71.

Explore the full profile